Logo
x

Search

Subscribe Now

Mutation

Amgen Reports NDA Submission of Sotorasib to the US FDA for Advanced/Metastatic NSCLC With KRAS G12C Mutation

Amgen Reports NDA Submission of Sotorasib to the US FDA for Advanced/Metastatic NSCLC With KRAS G12C Mutation

  • December 17, 2020
Roche Launches Cobas PIK3CA Mutation Test for Patients with Advanced or Metastatic Breast Cancer

Roche Launches Cobas PIK3CA Mutation Test for Patients with Advanced or Metastatic Breast Cancer

  • December 15, 2020
Amgen's Sotorasib Receives the US FDA's Breakthrough Therapy Designation for Advanced or Metastatic NSCLC with KRAS G12C Mutation

Amgen's Sotorasib Receives the US FDA's Breakthrough Therapy Designation for Advanced or Metastatic NSCLC with KRAS G12C Mutation

  • December 9, 2020
Novartis' Piqray (alpelisib) + Fulvestrant Receive FDA's Approval for Patients with a PIK3CA Mutation in HR+/HER2- Advanced/Metastatic Breast Cancer

Novartis' Piqray (alpelisib) + Fulvestrant Receive FDA's Approval for Patients with a PIK3CA Mutation in HR+/HER2- Advanced/Metast...

  • May 27, 2019
Vertex's Symdeko (tezacaftor/ivacaftor and ivacaftor) Receives TGA's Approval for Cystic Fibrosis with CFTR Gene Mutation in Australia

Vertex's Symdeko (tezacaftor/ivacaftor and ivacaftor) Receives TGA's Approval for Cystic Fibrosis with CFTR Gene Mutation in Austr...

  • March 13, 2019
Vertex's Kalydeco (ivacaftor) Receives Health Canada's Approval for Cystic Fibrosis (CF) with CFTR Gene Mutation in Children Aged 12 to

Vertex's Kalydeco (ivacaftor) Receives Health Canada's Approval for Cystic Fibrosis (CF) with CFTR Gene Mutation in Children Aged...

  • January 29, 2019
Image

Incisive News in 3 Shots.

Contact Us

Our Information

Follow Us

Copyright © 2024 PharmaShots - All Rights Reserved.